Merck Wins Keytruda Qlex Approval and Invests $70B in Diversification
Keytruda generated $29.5 billion in FY2024, or 46% of Merck’s $64.2 billion revenue, while non-Keytruda sales grew 3% despite China GARDASIL headwinds. Merck committed over $70 billion to manufacturing and R&D, won FDA approval for Keytruda Qlex in September 2025, and spent $19.2 billion on acquisitions to diversify.
1. Keytruda Concentration and Non-Keytruda Growth
Keytruda accounted for $29.5 billion or 46% of Merck’s $64.2 billion FY2024 revenue, underscoring high product concentration. Non-Keytruda pharmaceutical revenue rose 3% year-over-year despite a GARDASIL destocking headwind in China, highlighting early diversification progress.
2. Three Pillars of Diversification Strategy
Merck’s diversification rests on WINREVAIR’s expansion from pulmonary arterial hypertension into heart failure, the September 2025 FDA approval of subcutaneous Keytruda Qlex extending exclusivity beyond 2030, and a $3 billion cost restructuring targeting $1.7 billion in annual savings by 2027.
3. Strategic M&A and R&D Commitments
Merck has pledged over $70 billion to U.S. manufacturing and R&D, completed the $10 billion Verona Pharma acquisition and $9.2 billion Cidara purchase, and is evaluating a $28–32 billion deal for Revolution Medicines to deepen its pipeline.
4. Pipeline Depth and Financial Outlook
With approximately 80 Phase III trials across oncology, cardiovascular, infectious disease and immunology and more than 20 identified potential blockbusters, Merck projects cumulative mid-2030s revenue opportunities exceeding $50 billion and non-Keytruda sales reaching $39 billion by FY2027.